Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 5/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 3/20 | 0.32 |
| ▸ | POLQ | O75417 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.31 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.31 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MLYCD | O95822 | 1/20 | 0.31 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.30 |
| ▸ | F2R | P25116 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | BRAF | P15056 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23716797 | 0.95 | GPBAR1 (0.35) | GPBAR1DHODHPOLQKCNK3KCNK9 | |
| SCHEMBL30266971 | 0.95 | GPBAR1 (0.35) | GPBAR1DHODHPOLQKCNK3KCNK9 | |
| SCHEMBL23716778 | 0.91 | POLQ (0.38) | GPBAR1POLQMAPTKCNK3KCNK9 | |
| SCHEMBL21563800 | 0.91 | GPBAR1 (0.34) | GPBAR1DHODHPOLQMAPTP2RX1 | |
| SCHEMBL23716450 | 0.91 | GPBAR1 (0.33) | GPBAR1DHODHPOLQMLYCD | |
| SCHEMBL23716929 | 0.88 | SMN1; SMN2 (0.36) | GPBAR1POLQMAPTP2RX1 | |
| SCHEMBL23716447 | 0.86 | GPBAR1 (0.36) | GPBAR1DHODHPOLQP2RX1KCNK3 | |
| SCHEMBL21707901 | 0.86 | HDAC8 (0.39) | GPBAR1TSHRDHODHMAPTP2RX1 | |
| SCHEMBL24914867 | 0.85 | POLB (0.35) | GPBAR1TSHRPOLQMAPTP2RX1 | |
| SCHEMBL23059714 | 0.84 | GPBAR1 (0.34) | GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238126-A1 | Benzamide Compound and Use Thereof | METISA BIOTECHNOLOGY CO.,LTD. (CN) | 2021-08-05 | — | — | US | disclosed |
| WO-2019214588-A1 | BENZAMIDE COMPOUND AND APPLICATION THEREOF | 沈阳化工大学 (CN) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238126-A1 | Benzamide Compound and Use Thereof | TMBIM6, BCHE, DDT | GPBAR1 1655/4885TSHR 2922/4885DHODH 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.